Iovance Biotherapeutics, Inc. (IOVA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$8.79+1.03%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IOVA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 35.2% |
| Our one-year growth estimate | diamond | 50.3% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 15.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
IOVA — earnings miss
Dated 2026-05-07
Results of Operations and Financial Condition. On May 7, 2026, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026, and an update on recent developments. A copy of that press release is furnished as Exhibit 99.1. The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 193…
Why it matters: Trial results could show if lifileucel works for advanced sarcomas.
Watch forThe SARATOGA trial shows good results with high response rates.
Also watch forThe SARATOGA trial reports negative results with low or no response rates.
Why it matters: Maintaining cost discipline is crucial for Iovance to achieve its revenue goals. It impacts overall financial health.
Watch forManagement gives a clear update on cost control. This matches their revenue goals.
Also watch forManagement fails to address cost discipline in the next earnings call.
Why it matters: Higher cash burn may show problems in operations and affect future funding.
Worry ifCash burn exceeds $72M in 2Q26.
Less concerning ifCash burn remains below $72M in 2Q26.
Why it matters: This report will show how Iovance is managing its losses. Investors will look for signs of improvement.
Watch forEarnings show a smaller loss than last quarter. This means better cost management.
Also watch forEarnings report shows a larger loss than last quarter. This suggests worse financial health.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$302 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $712 loss on $10,000 · 7.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,900 loss on $10,000 · 39.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: If healthcare sector revenue growth speeds up, it may help Iovance's performance. It could signal a shift in market dynamics.
Supportive ifHealthcare sector revenue growth increases back toward 10% or higher.
Worry ifHealthcare sector revenue growth continues to slow below 10%.
Why it matters: Updates on the MAA resubmission could change market access and growth.
Watch forSuccessful resubmission of the MAA for lifileucel in the UK.
Also watch forMore delays or issues in the resubmission process.
Why it matters: Another earnings miss would signal ongoing challenges in meeting growth targets. This could hurt investor confidence.
Worry ifThe latest earnings report shows revenue is lower than expected.
Less concerning ifThe earnings report meets or is better than revenue expectations.
Why it matters: If they reach this goal, it shows they are growing. This is important for investor trust.
Supportive ifFY26 revenue reported at or above $350M.
Worry ifFY26 revenue reported below $350M.
Why it matters: Better operating income means they manage costs well. This is important for staying strong long-term.
Supportive ifOperating income improves further from -$81M in Q1 2026.
Worry ifOperating income worsens or stays at -$81M or worse.
Why it matters: An updated revenue guidance could signal strong demand trends and growth potential.
Supportive ifManagement raises FY26 revenue guidance to over $370 million. This is based on Q2 performance.
Worry ifGuidance stays the same or drops below $350 million.
Why it matters: Good results may help get lifileucel approved for new uses. This could boost growth.
Supportive ifPositive ORR results were shown at the ESMO meeting for the SARATOGA trial.
Worry ifResults show ORR below 30% or fail to meet expectations.
Why it matters: More centers could lead to higher patient access and increased revenue from Amtagvi.
Supportive ifThe number of authorized treatment centers will be over 110 by the end of 2026.
Worry ifThe number of authorized treatment centers fails to reach 110 by year-end.
Why it matters: Updates may show progress in the NSCLC area. This is important for Iovance's growth.
Watch forThere are positive updates on enrollment and results in the IOV-LUN-202 trial.
Also watch forNegative updates or delays in the trial's progress.